![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » OSI PHARMA'S TARCEVA APPROVED IN CANADA
OSI PHARMA'S TARCEVA APPROVED IN CANADA
OSI Pharmaceuticals has received Canadian approval Tarceva as a treatment for advanced or spreading lung cancer in patients who have not responded to chemotherapy.
The oral drug, which OSI developed with Genentech and Roche, is already approved for this indication in the U.S. and Switzerland. A European regulatory committee also has recommended approval of the drug. The approval applies to patients with non-small cell lung cancer, the most common form of the disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct